As healthcare systems worldwide are under immense pressure to bring the cost of new medicines under control, Most-Favored-Nation (MFN) pricing is becoming a crucial factor for both pharmaceutical and healthcare companies. Although MFN pricing promotes affordability and boosts the negotiating power of payers, it can also redefine the way drug prices are set, observed, and finalized in different markets. A price agreement signed in one country may affect pricing decisions in other countries via external reference pricing (ERP) networks, and as a result could impact global revenues, launch sequencing, portfolio investments, market access, and incentives decided for innovation. For pharmaceutical companies, therefore, understanding MFN pricing requires more than just monitoring U.S. policy. They need to have a wider perspective on how prices are negotiated, achieved, made public, and referenced in international markets.
How Could MFN Pricing Reshape Global Pharma Strategy?
Ingenious e-Brain’s whitepaper, “MFN Pricing: Reshaping Global Drug Pricing and Market Access,” uncovers the possible effects of MFN pricing and related mechanisms on reimbursement and market access across major global markets. It explores the interaction of international reference pricing, price transparency, gross-to-net dynamics, HTA and reimbursement mechanisms, launch sequencing, and cross-market price transmission.
Apart from the U.S., the whitepaper covers key regulatory policies for European and Asia-Pacific markets, highlighting how country-level pricing and reimbursement decisions can create downstream commercial implications. The analysis helps pharmaceutical companies evaluate potential exposure across markets and inform decisions on pricing governance, confidentiality, launch strategy, portfolio planning, market access, and MFN readiness.
What Can Readers Expect in This Whitepaper?
- MFN pricing principles, external & internal reference pricing, managed entry agreements, value-based arrangements, and other pricing mechanisms.
- MFN implications for patients, payers, manufacturers, HTA organizations, providers, and policymakers, including the balance between affordability and innovation.
- The U.S. MFN landscape, including policy evolution, international comparator baskets, pricing methodology, and potential implications for pharmaceutical pricing.
- Germany’s Erstattungsbetrag, its publication requirements, and its potential influence on pricing across multiple international reference markets.
- France and Italy’s confidential discounts, managed entry agreements, statutory discounts, retrospective mechanisms, and their impact on effective net-price visibility.
- Spain’s retail and hospital pricing channels, regional tendering structures, access delays, and downstream reference-price exposure.
- The UK’s NICE cost-effectiveness framework, VPAG, confidential agreements, list vs. net pricing, and role in international reference baskets.
- Japan’s Foreign Average Price (FAP) mechanism, scheduled price revisions, and the potential for international price signals to flow into and out of the market.
- Australia’s PBAC framework, AEMP, confidential Special Pricing Arrangements, competitor patent expiry, and the distinction between published and effective prices.
Understand how MFN could reshape drug pricing worldwide, market access, and pharmaceutical strategy.
Fill out the form to access the whitepaper.
